여성 건강 진단 시장 보고서 : 유형, 용도, 최종사용자, 지역별(2026-2034년)

The global women's health diagnostics market size reached USD 33.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 56.1 Billion by 2034, exhibiting a growth rate (CAGR) of 5.86% during 2026-2034. The market is propelled by the rising number of individuals diagnosed with chronic and lifestyle-related diseases, significant technological developments in diagnostic services, increasing awareness about women's health through numerous campaigns and initiatives by the governments and public organizations, increasing acceptance rate of point-of-care diagnostics, and rapid growth in telemedicine and remote diagnostics industry.

WOMEN'S HEALTH DIAGNOSTICS MARKET ANALYSIS :

• Major Market Drivers: Some of the major market drivers include the rising number of individuals diagnosed with chronic and lifestyle-related diseases, significant technological developments, and rising awareness and emphasis on the health of women.
• Key Market Trends: Rapid growth of the telemedicine and remote diagnostics market, increasing adoption of point-of-care diagnostics, and increasing number of research and development (R&D) activities are some key market trends of the industry.
• Geographical Trends: North America dominates the women's health diagnostics industry due to its robust health infrastructure and cutting-edge competition within the industry. Europe holds second position on account of the rising number of individuals diagnosed with chronic diseases and increasing awareness about women's health.
• Competitive Landscape: Abbott Laboratories, Aspira Women's Health, Becton Dickinson and Company, bioMerieux, Cepheid (Danaher Corporation), F. Hoffmann-La Roche Ltd, GE HealthCare, Hologic, Inc., Koninklijke Philips N.V., Quest Diagnostics, Siemens Healthineers AG and Thermo Fisher Scientific Inc., are among some of the key players in the women's health diagnostics industry.
• Challenges and Opportunities: Women's health diagnostics market recent opportunities include positioning in untapped markets and significant developments in personalized genomics and medicine. Whereas, challenges include expensive diagnostic tests and equipment and restricted access to healthcare facilities in rural regions.

WOMEN'S HEALTH DIAGNOSTICS MARKET TRENDS :

Substantial Rise in the Number of Females Diagnosed with Chronic and Lifestyle-Related Disorders

One of the primary factors driving the market is the increasing prevalence of chronic and lifestyle-related diseases amongst women. These include, cervical cancer, osteoporosis, cardiovascular diseases, and breast cancer. According to the WORLD HEALTH ORGANIZATION (WHO), breast cancer is one of the leading causes of death among women globally. Approximately 2.3 million women were diagnosed with breast cancer and 6,70,000 succumbed to it globally, in the year 2022. The report also states that in nations with an exceptionally high Human Development Index (HDI), the chances of occurrence of breast cancer is relatively high as compared to nations with a lower HDI. This increasing prevalence of these diseases is leading to a higher women's health diagnostics demand globally. One of the leading causes of these diseases is the sedentary lifestyles and poor dietary habits, which also lead to illnesses such as obesity and diabetes. Chronic illnesses usually require constant monitoring and management, thereby propelling the market growth. Other than this, the rising awareness about the importance of early detection is also playing a vital role.

Rising Government Initiatives

The rising government initiatives in order to spread awareness about the chronic illnesses prevalent amongst women, is creating a positive women's health diagnostics market overview. The increased awareness and education associated with the distinctive health challenges faced by women in confluence with the importance of regular health screenings is driving the market. In order to achieve this, governments, non-profit, and public organizations organize campaigns focusing on the importance of early detection and preventive care. One of the most renowned campaigns for breast cancer is the BREAST CANCER AWARENESS MONTH, which runs through the entire month of October. This initiative was started in the year 1985 through a productive collaboration between the AMERICAN CANCER SOCIETY and IMPERIAL CHEMICAL INDUSTRIES, which is ever since a part of ASTRAZENECA, a major producer of breast cancer medications. The campaign increases awareness around the disease and also raises funds for its treatments, and research. The awareness month includes numerous social media campaigns, walking events, and races taking place across the globe.

Rising Acceptance of Point-of-Care Diagnostics

The increasing acceptance of point-of-care diagnostics is further driving the women's health diagnostics market growth. The rising adoption of this type of diagnostics can be attributed to the advantage of conducing diagnostic tests nearby the patient, thereby offering immediate results and allowing faster clinical decision-making. This technique is majorly useful in cases where timely diagnosis can significantly impact treatment directions, such as in pregnancy-related complexities, cancer screenings, and sexually transmitted infections. According to a report published by the IMARC GROUP, the global point-of-care diagnostics market reached US$ 49.2 Billion in 2023, and is projected to reach US$ 99.5 Billion by 2032, reflecting a CAGR of 7.9% during 2024-2032. The report further mentioned numerous key players entering in partnerships in order to offer distinctive and dependable diagnostic solutions in order to transform the healthcare delivery. For instance, MOLBIO DIAGNOSTICS announced its collaboration with SIGTUPLE in the year 2023, for the development of next-generation AI-enabled movable devices for numerous routine and diagnostic tests.

WOMEN'S HEALTH DIAGNOSTICS INDUSTRY SEGMENTATION:

Breakup by Type:

• Diagnostic Devices
  • Biopsy Device
  • Imaging and Monitoring Devices
  • Accessories and Consumables
• Diagnostic Tests
  • Breast Cancer Testing
  • PAP Smear and HPV Test
  • Pregnancy Testing and Ovulation Testing
  • Others

Diagnostic Devices accounts for the majority of the market share

According to the women's health diagnostics forecast, diagnostic services dominate the market on account of the wide array of vital tests and screening possessed by them, which are important for early detection and management of numerous health conditions. Some of the most commonly available services include ultrasound, PAP smear tests, mammography, and blood tests which assist in the routine monitoring of specific conditions related to women's health. Other than this, the rising number of females suffering with chronic illnesses is leading to a rise in the demand for regular health check up drives, thereby creating a positive women's health diagnostics outlook. Moreover, the diagnostic services maintain a leading position within the industry also on account of the rising prevalence of the home diagnostic services. As per a market research report published by GITNUX, the global home diagnostics market is projected to reach USD 6.53 Billion by 201-2025.

Breakup by Application:

• Breast Cancer
• Infectious Disease Testing
• Osteoporosis Testing
• Pregnancy and Fertility Testing
• Sexually Transmitted Disease Testing

Infectious disease testing holds the largest share in the industry

Infectious disease testing dominates the market growth on account of the rising number of sexually-transmitted infections (STIs) and numerous other communicable diseases. According to the WORLD HEALTH ORGANIZATION (WHO), more than 1 million individuals are diagnosed with sexually transmitted diseases (ATIs) every single day, globally. Majority of these diagnosed cases are asymptomatic. In order to seamlessly and effectively manage these conditions, there is a crucial requirement for appropriate management and treatment solutions. Other than this, the rising awareness amongst individuals regarding these conditions is also driving the infectious disease testing market. According to GITNUX, the infectious disease testing market is exhibiting a CAGR of 7% during 2021-2026. Moreover, governments and public organizations across the globe are taking initiatives to promote regular testing for these diseases.

Breakup by End User:

• Hospital and Diagnostics Centers
• Home Care

Hospital and diagnostics centers represent the leading market segment

Hospital and diagnostic centers represent the largest segment on account of their holistic healthcare services, developed diagnostic technologies, and capability to handle a high volume of patients. These services provide customized expertise and infrastructure for precise and early detection of complicated health conditions which seek effective treatment planning beforehand. Other than this, the rising number of hospitals globally is also a significant factor driving the market. According to the AMERICAN HOSPITAL ASSOCITION, there are 6,120 hospitals in the United States. These centers are usually the first point of care for numerous females seeking medical aid, which further contributes positively to the women's health diagnostic market revenue.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest women's health diagnostics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America dominates the market on account of its robust healthcare infrastructure, presence of prominent key players and a significant rise in the healthcare expenditure across the United States. According to the AMERICAN MEDICAL ASSOCIATION (AMA), the health spending in the United States increased by 4.1% in 2022 to $4.4 Trillion or $13,493 per capita. The region particularly places a significant emphasis on early diagnosis and preventive care, in confluence with significant investment in research and development (R&D) activities thereby driving the market growth. Other factors driving the market include rising awareness campaigns, favorable reimbursement policies which further support the adoption of women's health diagnostics recent developments.

COMPETITIVE LANDSCAPE:

Major women's health diagnostics companies are significantly focusing on innovation and improving their product portfolios in order to improve diagnostic accuracy and efficiency. Additionally, they are also investing substantially in research and development (R&D) activities in order to launch advanced technologies including molecular diagnostics, AI-driven diagnostic tools, and next-generation sequencing. Prominent key players are also entering into strategic collaborations and acquisitions in order to enter untapped markets. For instance, in April 2023 QUEST DIAGNOSTICS and NEW YORK-PRESBYTERIAN announced that the former completes its acquisition fo selected assets of the laboratory services business of NEWYORK- PRESBYTERIAN. This strategic collaboration in meant to enable providers and patients to access good-quality, economical testing from a service menu that integrates the complementary strengths of both organizations.

The report provides a comprehensive analysis of the competitive landscape in the global women's health diagnostics market with detailed profiles of all major companies, including:

• Abbott Laboratories
• Aspira Women's Health
• Becton Dickinson and Company
• bioMerieux
• Cepheid (Danaher Corporation)
• F. Hoffmann-La Roche Ltd
• GE HealthCare
• Hologic, Inc.
• Koninklijke Philips N.V.
• Quest Diagnostics
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Women's Health Diagnostics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Diagnostic Devices
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Biopsy Device
    • 6.1.2.2 Imaging and Monitoring Devices
    • 6.1.2.3 Accessories and Consumables
  • 6.1.3 Market Forecast
• 6.2 Diagnostic Tests
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Breast Cancer Testing
    • 6.2.2.2 PAP Smear and HPV Test
    • 6.2.2.3 Pregnancy Testing and Ovulation Testing
    • 6.2.2.4 Others
  • 6.2.3 Market Forecast

7 Market Breakup by Application

• 7.1 Breast Cancer
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Infectious Disease Testing
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Osteoporosis Testing
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Pregnancy and Fertility Testing
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Sexually Transmitted Disease Testing
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospital and Diagnostics Centers
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Home Care
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Aspira Women's Health
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Becton Dickinson and Company
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 bioMerieux
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Cepheid (Danaher Corporation)
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 F. Hoffmann-La Roche Ltd
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 GE HealthCare
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Hologic, Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Koninklijke Philips N.V.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Quest Diagnostics
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Siemens Healthineers AG
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Thermo Fisher Scientific Inc.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis